Critical Role of Spatial Interaction Between CD8⁺ and Foxp3⁺ Cells in Human Gastric Cancer: the Distance Matters
Overview
Oncology
Pharmacology
Authors
Affiliations
Purpose: In various cancer types, an abundance of FoxP3(+) regulatory T cells (Treg) has been associated with an unfavorable outcome. Yet, the role of Treg on cancer immunity has been shown to be complex. In single cell marker technique, other tumor-infiltrating lymphocytes (TILs) such as cytotoxic CD8(+) T cells (CTL) also influenced prognosis. This study for the first time investigates the concurrent spatial distribution pattern of CD8(+) and FoxP3(+) TILs and their prognostic impact in human gastric cancer.
Materials And Methods: Tumor tissue microarrays of 50 patients with surgically treated adenocarcinoma of the cardia were studied. An immunohistochemical double staining of CD8(+) and FoxP3(+) TILs was performed. Cell counts and cell-to-cell distances in tumor epithelium and stroma were evaluated with image-processing software. Metastasis-free survival, no-evidence-of-disease survival, and overall survival were investigated (mean follow-up time 6.9 years).
Results: High intraepithelial infiltration of CD8(+) and FoxP3(+) TIL was associated with the improved 10-year metastasis-free survival (83 vs. 54%, p = 0.04 and 85 vs. 59%, p = 0.09, respectively). Considering cell-to-cell distance and comparing patients with functional (30-110 μm) versus nonfunctional distances of CD8(+) and FoxP3(+) TILs, 10-year survival rates differed between 89 and 55% (p = 0.009), respectively.
Conclusion: Prognostic influence of tumor-infiltrating immune cells in gastric cancer critically depends on their cell-to-cell distance. FoxP3(+) TILs must be located within a distance between 30 and 110 μm of CD8(+) T cells to positively impact on prognosis.
Chakraborti S, Paul R, Pal M, Chatterjee J, Das R Indian J Otolaryngol Head Neck Surg. 2025; 77(2):929-938.
PMID: 40070771 PMC: 11890828. DOI: 10.1007/s12070-024-05305-3.
Ren Z, Wang Y, Jiang D, Liu Y, Yang X, Wang T Cancer Immunol Immunother. 2025; 74(3):109.
PMID: 39937280 PMC: 11822157. DOI: 10.1007/s00262-025-03962-z.
Alekseenko I, Zhukova L, Kondratyeva L, Buzdin A, Chernov I, Sverdlov E Int J Mol Sci. 2024; 25(19).
PMID: 39408784 PMC: 11476449. DOI: 10.3390/ijms251910454.
Cai S, Yang G, Hu M, Li C, Yang L, Zhang W Cancer Immunol Immunother. 2024; 73(10):189.
PMID: 39093404 PMC: 11297009. DOI: 10.1007/s00262-024-03762-x.
Zhou Z, Wang J, Wang J, Yang S, Wang R, Zhang G Mol Cancer. 2024; 23(1):131.
PMID: 38918817 PMC: 11201788. DOI: 10.1186/s12943-024-02047-2.